These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1378 related articles for article (PubMed ID: 23415222)

  • 21. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
    Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
    Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.
    Ojha J; Ayres J; Secreto C; Tschumper R; Rabe K; Van Dyke D; Slager S; Shanafelt T; Fonseca R; Kay NE; Braggio E
    Blood; 2015 Jan; 125(3):492-8. PubMed ID: 25377784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene mutations in chronic lymphocytic leukemia.
    Amin NA; Malek SN
    Semin Oncol; 2016 Apr; 43(2):215-21. PubMed ID: 27040699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
    Rasi S; Khiabanian H; Ciardullo C; Terzi-di-Bergamo L; Monti S; Spina V; Bruscaggin A; Cerri M; Deambrogi C; Martuscelli L; Biasi A; Spaccarotella E; De Paoli L; Gattei V; Foà R; Rabadan R; Gaidano G; Rossi D
    Haematologica; 2016 Apr; 101(4):e135-8. PubMed ID: 26819056
    [No Abstract]   [Full Text] [Related]  

  • 25. Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy.
    Zapatka M; Tausch E; Öztürk S; Yosifov DY; Seiffert M; Zenz T; Schneider C; Blöhdorn J; Döhner H; Mertens D; Lichter P; Stilgenbauer S
    Haematologica; 2022 Mar; 107(3):604-614. PubMed ID: 33691380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
    Gunnarsson R; Mansouri L; Isaksson A; Göransson H; Cahill N; Jansson M; Rasmussen M; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Geisler C; Juliusson G; Rosenquist R
    Haematologica; 2011 Aug; 96(8):1161-9. PubMed ID: 21546498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYC copy number and mRNA expression in chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chornobyl NPP accident.
    Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
    Exp Oncol; 2020 Mar; 42(1):60-65. PubMed ID: 32231192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.
    Sutton LA; Rosenquist R
    Semin Cancer Biol; 2015 Oct; 34():22-35. PubMed ID: 25963298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression.
    Ojha J; Secreto C; Rabe K; Ayres-Silva J; Tschumper R; Dyke DV; Slager S; Fonseca R; Shanafelt T; Kay N; Braggio E
    Leukemia; 2014 Dec; 28(12):2395-8. PubMed ID: 25034147
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.
    Shuai W; Lin P; Strati P; Patel KP; Routbort MJ; Hu S; Wei P; Khoury JD; You MJ; Loghavi S; Tang Z; Fang H; Thakral B; Medeiros LJ; Wang W
    Blood Cancer J; 2020 Aug; 10(8):86. PubMed ID: 32848129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.
    Quijada-Álamo M; Hernández-Sánchez M; Robledo C; Hernández-Sánchez JM; Benito R; Montaño A; Rodríguez-Vicente AE; Quwaider D; Martín AÁ; García-Álvarez M; Vidal-Manceñido MJ; Ferrer-Garrido G; Delgado-Beltrán MP; Galende J; Rodríguez JN; Martín-Núñez G; Alonso JM; García de Coca A; Queizán JA; Sierra M; Aguilar C; Kohlmann A; Hernández JÁ; González M; Hernández-Rivas JM
    J Hematol Oncol; 2017 Apr; 10(1):83. PubMed ID: 28399885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
    Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
    Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
    Stamatopoulos B; Timbs A; Bruce D; Smith T; Clifford R; Robbe P; Burns A; Vavoulis DV; Lopez L; Antoniou P; Mason J; Dreau H; Schuh A
    Leukemia; 2017 Apr; 31(4):837-845. PubMed ID: 27795555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease.
    Rose-Zerilli MJ; Gibson J; Wang J; Tapper W; Davis Z; Parker H; Larrayoz M; McCarthy H; Walewska R; Forster J; Gardiner A; Steele AJ; Chelala C; Ennis S; Collins A; Oakes CC; Oscier DG; Strefford JC
    Leukemia; 2016 Jun; 30(6):1301-10. PubMed ID: 26847028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
    Ahn IE; Underbayev C; Albitar A; Herman SE; Tian X; Maric I; Arthur DC; Wake L; Pittaluga S; Yuan CM; Stetler-Stevenson M; Soto S; Valdez J; Nierman P; Lotter J; Xi L; Raffeld M; Farooqui M; Albitar M; Wiestner A
    Blood; 2017 Mar; 129(11):1469-1479. PubMed ID: 28049639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival.
    Stilgenbauer S; Sander S; Bullinger L; Benner A; Leupolt E; Winkler D; Kröber A; Kienle D; Lichter P; Döhner H
    Haematologica; 2007 Sep; 92(9):1242-5. PubMed ID: 17666364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.
    Navrkalova V; Plevova K; Radova L; Porc J; Pal K; Malcikova J; Pavlova S; Doubek M; Panovska A; Kotaskova J; Pospisilova S
    Br J Haematol; 2024 Jan; 204(1):240-249. PubMed ID: 38062779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.